The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled ``Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017.'' This guidance concerns FDA's implementation of the Prescription Drug User Fee Amendments of 2017 (PDUFA VI) and certain changes in policies and procedures surrounding its application.
Document
Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled ``Assessing User Fees Under the Prescription Drug User ...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 19564
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017; Guidance for Industry; Availability,” thefederalregister.org (May 3, 2018), https://thefederalregister.org/documents/2018-09366/assessing-user-fees-under-the-prescription-drug-user-fee-amendments-of-2017-guidance-for-industry-availability.